Sentai Ding

机构：Shandong Provincial Hospital, Shandong First Medical University

发表论文 76 篇 · 总被引 780 次 · h-index 17

代表论文

• Neoadjuvant gemcitabine–cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial (2024 · Nature Cancer · 被引 23)
• Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients (2024 · Frontiers in Pharmacology · 被引 17)
• Hypoxia activates the hypoxia-inducible factor-1α/vascular endothelial growth factor pathway in a prostatic stromal cell line: A mechanism for the pathogenesis of benign prostatic hyperplasia (2023 · Current Urology · 被引 6)
• Immune checkpoint inhibitor therapy as a neoadjuvant treatment for muscle-invasive bladder carcinoma: A narrative review (2024 · Current Urology · 被引 5)
• 320MO Tibremciclib (BPI-16350) plus fulvestrant in patients with HR+/HER2- advanced breast cancer after progressing on endocrine therapy: A randomized, multicenter, double-blind, phase III study (2024 · Annals of Oncology · 被引 4)
• Expression of HER2 in urothelial carcinoma and its significance (2024 · Current Urology · 被引 4)